LeMaitre
Makes vascular grafts, patches, and shunts while providing human-tissue cryopreservation services.
Something off on this page? Send us feedback.
Profile
Sells vascular grafts, patches, shunts, catheters, and related surgical devices, alongside human-tissue processing and cryopreservation services. A focused direct sales force generates most revenue, with all product lines and services reported in one operating segment.
Develops, manufactures, and markets devices and implants used mainly in vascular surgery, while processing and cryopreserving human vascular and cardiac tissue. Core lines include biologic and synthetic vascular and dialysis grafts, vascular and cardiac patches, carotid shunts, valvulotomes, embolectomy and occlusion catheters, anastomotic clips, and radiopaque marking tape.
Sells primarily to hospitals through a focused direct sales force, with distributors covering other territories. Products reach the United States, Europe, Canada, and Asia Pacific, and the commercial model uses the same specialist channel to add complementary products and convert selected distributor markets to direct sales.
Operates as one segment. Demand follows vascular, dialysis, and cardiovascular procedures, while manufacturing and tissue processing remain subject to medical-device and human-tissue regulation across the markets served.
Company facts
Categories
Key statistics
Year to date +0.4% · Average volume (30d) 393.1K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | Barrington | Target | $120 | $95 | ||
| May 6, 2026 | Lake Street | Target | $110 | $135 | ||
| May 6, 2026 | Barrington | Target | $120 | |||
| Nov 10, 2025 | Cantor Fitzgerald | Target | $96 | $95 | ||
| Nov 5, 2025 | Roth Capital | Target | $108 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | $0.81 | $0.74 | −8.3% | $71.5M | $70.4M | −1.5% | −25.32% |
| May 5, 2026Q1 FY26 | $0.66 | $0.68 | +3.0% | $66.7M | $66.6M | −0.2% | −1.59% |
| Feb 25, 2026Q4 FY25 | $0.67 | $0.68 | +1.5% | $62.8M | $64.5M | +2.6% | +24.41% |
| Nov 6, 2025Q3 FY25 | $0.56 | $0.62 | +9.9% | $62.2M | $61.0M | −1.8% | +1.43% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $59.9M | $64.2M | $61.0M | $64.5M | $66.6M | $70.4M | |
| Gross profit | $41.4M | $45.0M | $46.0M | $46.2M | $48.4M | $50.8M | |
| Operating income | $12.6M | $16.1M | $20.3M | $18.8M | $17.8M | $20.4M | |
| Net income | $11.0M | $13.8M | $17.4M | $15.6M | $15.7M | $17.1M | |
| Diluted EPS | $0.48 | $0.60 | $0.75 | $0.68 | $0.68 | $0.74 | |
| Gross margin | 69.2% | 70.0% | 75.3% | 71.7% | 72.7% | 72.1% | |
| Operating margin | 21.1% | 25.1% | 33.3% | 29.2% | 26.7% | 29.0% |
Fiscal years (4-quarter sums)FY21 $154.4M · FY22 $161.7M · FY23 $193.5M · FY24 $219.9M · FY25 $249.6M
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $376.2M · Total debt $190.3M · Total assets $640.5M · Shareholders' equity $420.3M
Dividends
Raised for 14 straight years — most recently to $0.25 from $0.20 in Mar 2026. To collect a payout, hold shares through the close before the ex-date.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Aug 20, 2026 | Aug 20 | Sep 3 | $0.25 | |
| May 21, 2026 | May 21 | Jun 4 | $0.25 | |
| Mar 12, 2026 | Mar 12 | Mar 26 | $0.25 | raised from $0.20 |
| Nov 20, 2025 | Nov 20 | Dec 4 | $0.20 | |
| Aug 21, 2025 | Aug 21 | Sep 4 | $0.20 | |
| May 15, 2025 | May 15 | May 29 | $0.20 | |
| Mar 13, 2025 | Mar 13 | Mar 27 | $0.20 | raised from $0.16 |
| Nov 21, 2024 | Nov 21 | Dec 5 | $0.16 |
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 22.85M · Float 21.27M · 93.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 3.27M | 14.32% | 13F | Aug 7, 2026 |
| George W. LeMaitre · director, officer: Chairman and CEO | 1.46M | 6.40% | Form 4 | Jun 5, 2026 |
| Conestoga Capital Advisors, LLC | 1.37M | 5.98% | 13F | Jul 24, 2026 |
| First Trust Portfolios L.P. | 1.18M | 5.15% | 13G | Jul 27, 2026 |
| First Trust Advisors LP | 1.09M | 4.79% | 13F | Aug 11, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 7, 2026 | Lawrence J. Jasinski | director | −3,943 | $110.00 |
| May 7, 2026 | Bridget A. Ross | director | −5,044 | $111.10 |
| May 8, 2026 | Trent G. Kamke | officer: Senior V. P., Operations | −2,928 | $107.00 |
| May 8, 2026 | George W. LeMaitre | director, officer: Chairman and CEO | −27,881 | $108.69 |
| May 7, 2026 | George W. LeMaitre | director, officer: Chairman and CEO | −18,600 | $107.64 |
Peers
- BD
Broad peripheral vascular overlap through Bard devices
- Artivion
Focused tissue and graft rival in cardiac and vascular surgery
- Abbott
Vascular intervention giant pressuring open-surgery niches
- Edwards Lifesciences
Cardiac surgery overlap around valves and repair products
- Humacyte
Bioengineered vascular conduit challenger
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| LeMaitre | $80.45 | −0.01% | $1.84B | 28.2 | 26.3 | 7.0 | +9.6% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| Artivion | $26.77 | +0.11% | $1.30B | — | 80.9 | 2.8 | +11.3% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Edwards Lifesciences | $91.14 | +1.04% | $51.94B | 51.8 | 28.7 | 8.0 | +13.6% |
| Humacyte | $0.6557 | +0.83% | $109.2M | — | — | 51.5 | +34.9% |
| Median | 51.8 | 24.1 | 4.2 | +13.0% |